VeracyteVCYT +4.06%75 Days Payable is 13.84 as of Mar. 2026, which is 60% below its 10-year median of 34.84. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.10 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Veracyte ranks worse than 89.01% on this metric.
Veracyte's average Accounts Payable for the
three
months ended in Mar. 2026 was $5.8 Mil. Veracyte's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $37.9 Mil.
Hence, Veracyte's Days Payable for the
three
months ended in Mar. 2026 was 13.84.
The historical rank and industry rank for Veracyte's Days Payable or its related term are showing as below:
VCYT'
s Days Payable Range Over the Past 10 Years
Min: 15.61 Med: 34.84 Max: 53.82
Current: 20.46
During the past 13 years, Veracyte's highest Days Payable was 53.82. The lowest was 15.61. And the median was 34.84.
VCYT's Days Payable is ranked worse than 89.01% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs VCYT: 20.46
Veracyte's Days Payable
declined
from Mar. 2025 (31.76) to Mar. 2026 (13.84).
It may suggest that Veracyteaccelerated paying its suppliers.
Veracyte Days Payable Related Terms
Veracyte Days Payable Historical Data
* Premium members only.
The historical data trend for Veracyte's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Veracyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Days Payable distribution charts can be found below:
* The bar in red indicates where Veracyte's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Veracyte's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a Days Payable of 13.84 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veracyte and its competitors. This is 60% below median its historical median of 34.84. Over the past decade, Veracyte's Days Payable has ranged from 15.61 to 53.82. According to the industry distribution chart, Veracyte ranks #170 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 89%.
Is Veracyte's Days Payable too high?
Veracyte's current Days Payable of 13.84 is 60% below median its 10-year median of 34.84. Over the past 10 years, this metric has ranged from a low of 15.61 to a high of 53.82. The Medical Diagnostics & Research industry median Days Payable is 68.87. Veracyte's value of 13.84 is 79.9% below this industry median. Based on the distribution chart, Veracyte ranks #170 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Days Payable compare to TWST and GRAL?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #170 out of 191 companies for Days Payable. This places Veracyte in the lower half of its industry. The industry median Days Payable is 68.87. Veracyte's value of 13.84 is 79.9% below this benchmark. Historically, Veracyte's own Days Payable has ranged from 15.61 to 53.82 over the past decade. While the company's 10-year median is 34.84 vs. the industry median of 68.87, Veracyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current Days Payable of 13.84 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current Days Payable is 13.84, which is 60% below median its own 10-year median of 34.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.10, compared to a current price of $59.07 — trading 55% above its estimated fair value. The current Days Payable is 13.84, which is 60% below median its 10-year median of 34.84 and 79.9% below the Medical Diagnostics & Research industry median of 68.87. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Veracyte (VCYT), the current Days Payable is 13.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $59.07 is trading 55% above its estimated GF Value™ of $38.10.
GuruFocus considers Veracyte to be Significantly Overvalued.
Key valuation signals for VCYT:
Days Payable: 13.84 (60% below median its 10-year median of 34.84)
GF Value™: $38.10 vs. price of $59.07 (55% above fair value)
Industry Position: 79.9% below the Medical Diagnostics & Research median (#170 of 191)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score
Get the complete analysis for VCYT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
